Single-Cell Identification of Melanoma Biomarkers in Circulating Tumor Cells

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Oct 14

PMID 36230844

Authors

Reilly Fankhauser

Matthew Chang

Zachary Garrison

Rachel Berryman

Olivia M Lucero

Allison Fuiten

Nicholas DePatie

Hilary Seifert

Rajan P Kulkarni

Affiliations

Soon will be listed here.

Abstract

The current standard for investigating tumors is surgical biopsy, which is costly, invasive, and difficult to perform serially. As an adjunct, circulating tumor cells (CTCs)-cells that have broken away from the primary tumor or metastatic sites-can be obtained from a blood draw and offer the potential for obtaining serial genetic information and serving as biomarkers. Here, we detail the potential for melanoma CTCs to serve as biomarkers and discuss a clinically viable methodology for single-cell CTC isolation and analysis that overcomes previous limitations. We explore the use of melanoma CTC biomarkers by isolating and performing single-cell RNA sequencing on CTCs from melanoma patients. We then compared transcriptional profiles of single melanoma CTCs against A375 cells and peripheral blood mononuclear cells to identify unique genes differentially regulated in circulating melanoma tumor cells. The information that can be obtained via analysis of these CTCs has significant potential in disease tracking.

Citing Articles

The Dynamic Landscape of the Coagulome of Metastatic Malignant Melanoma.

Arnault J, Chemmama K, Ferroudj K, Demagny J, Panicot-Dubois L, Galmiche A Int J Mol Sci. 2025; 26(4).

PMID: 40003901 PMC: 11855523. DOI: 10.3390/ijms26041435.

Melanoma's New Frontier: Exploring the Latest Advances in Blood-Based Biomarkers for Melanoma.

Prkacin I, Mokos M, Ferara N, Situm M Cancers (Basel). 2025; 16(24.

PMID: 39766118 PMC: 11727356. DOI: 10.3390/cancers16244219.

The Emerging Role of Liquid Biopsies in Revolutionising Cancer Diagnosis and Therapy.

Shegekar T, Vodithala S, Juganavar A Cureus. 2023; 15(8):e43650.

PMID: 37719630 PMC: 10505053. DOI: 10.7759/cureus.43650.

Advances in single-cell RNA sequencing and its applications in cancer research.

Huang D, Ma N, Li X, Gou Y, Duan Y, Liu B J Hematol Oncol. 2023; 16(1):98.

PMID: 37612741 PMC: 10463514. DOI: 10.1186/s13045-023-01494-6.

References

Joosse S, Gorges T, Pantel K . Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2014; 7(1):1-11. PMC: 4309663. DOI: 10.15252/emmm.201303698. View

Rapanotti M, Campione E, Spallone G, Orlandi A, Bernardini S, Bianchi L . Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146. Cell Death Discov. 2017; 3:17005. PMC: 5337524. DOI: 10.1038/cddiscovery.2017.5. View

Dissanayake S, Wade M, Johnson C, OConnell M, Leotlela P, French A . The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem. 2007; 282(23):17259-71. PMC: 2263117. DOI: 10.1074/jbc.M700075200. View

Klinac D, Gray E, Freeman J, Reid A, Bowyer S, Millward M . Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer. 2014; 14:423. PMC: 4060872. DOI: 10.1186/1471-2407-14-423. View

Alix-Panabieres C, Schwarzenbach H, Pantel K . Circulating tumor cells and circulating tumor DNA. Annu Rev Med. 2011; 63:199-215. DOI: 10.1146/annurev-med-062310-094219. View

Stott S, Lee R, Nagrath S, Yu M, Miyamoto D, Ulkus L . Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010; 2(25):25ra23. PMC: 3141292. DOI: 10.1126/scitranslmed.3000403. View

DallOlio F, Gelsomino F, Conci N, Marcolin L, De Giglio A, Grilli G . PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Clin Lung Cancer. 2021; 22(5):423-431. DOI: 10.1016/j.cllc.2021.03.005. View

Spranger S, Bao R, Gajewski T . Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015; 523(7559):231-5. DOI: 10.1038/nature14404. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

10.

Pilloni L, Bianco P, Difelice E, Cabras S, Castellanos M, Atzori L . The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions. Eur J Histochem. 2011; 55(2):e20. PMC: 3284155. DOI: 10.4081/ejh.2011.e20. View

11.

Webster M, Kugel 3rd C, Weeraratna A . The Wnts of change: How Wnts regulate phenotype switching in melanoma. Biochim Biophys Acta. 2015; 1856(2):244-51. PMC: 4668201. DOI: 10.1016/j.bbcan.2015.10.002. View

12.

Gascoyne P, Shim S . Isolation of circulating tumor cells by dielectrophoresis. Cancers (Basel). 2014; 6(1):545-79. PMC: 3980488. DOI: 10.3390/cancers6010545. View

13.

Picelli S, Faridani O, Bjorklund A, Winberg G, Sagasser S, Sandberg R . Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc. 2014; 9(1):171-81. DOI: 10.1038/nprot.2014.006. View

14.

Vitale I, Shema E, Loi S, Galluzzi L . Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med. 2021; 27(2):212-224. DOI: 10.1038/s41591-021-01233-9. View

15.

Freeman J, Gray E, Millward M, Pearce R, Ziman M . Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. J Transl Med. 2012; 10:192. PMC: 3480925. DOI: 10.1186/1479-5876-10-192. View

16.

Santamaria P, Floristan A, Fontanals-Cirera B, Vazquez-Naharro A, Santos V, Morales S . Lysyl oxidase-like 3 is required for melanoma cell survival by maintaining genomic stability. Cell Death Differ. 2017; 25(5):935-950. PMC: 5907912. DOI: 10.1038/s41418-017-0030-2. View

17.

Pantel K, Alix-Panabieres C, Riethdorf S . Cancer micrometastases. Nat Rev Clin Oncol. 2009; 6(6):339-51. DOI: 10.1038/nrclinonc.2009.44. View

18.

Xue G, Romano E, Massi D, Mandala M . Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights. Cancer Treat Rev. 2016; 49:1-12. DOI: 10.1016/j.ctrv.2016.06.009. View

19.

Holtzhausen A, Zhao F, Evans K, Tsutsui M, Orabona C, Tyler D . Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. Cancer Immunol Res. 2015; 3(9):1082-95. PMC: 4927300. DOI: 10.1158/2326-6066.CIR-14-0167. View

20.

Da Forno P, Pringle J, Hutchinson P, Osborn J, Huang Q, Potter L . WNT5A expression increases during melanoma progression and correlates with outcome. Clin Cancer Res. 2008; 14(18):5825-32. DOI: 10.1158/1078-0432.CCR-07-5104. View